Abstract: A light-emitting-diode-driving device includes a control circuit that is configured to perform constant current control with a DC-DC converter so that a value of a current detected by a current detection unit agrees with a prescribed reference current value to be supplied to a light source. The control circuit includes a reference-current-instruction unit, a threshold-voltage-setting unit, and a comparator circuit. The reference-current-instruction unit is configured to set the prescribed reference current value. The threshold-voltage-setting unit is configured to set a threshold voltage for determining a short circuit failure in the light source. The comparator circuit is configured to compare, with the threshold voltage, a value of a voltage that is detected by a voltage detection unit. The control circuit is configured to make the threshold-voltage-setting unit reduce the threshold voltage, when the reference-current-instruction unit reduces the prescribed reference current value.

Abstract: Provided is a printed circuit board (1) on which the power supply circuit is mounted and a casing (2) which is shaped like a flat as a whole and in which the printed circuit board (1) is housed. An input terminal (11) of the power supply circuit is connected to an input socket (3) fixed to one end part, in a direction perpendicular to a thickness direction of the printed circuit board (1), of the casing. An output terminal (12) of the power supply circuit is connected to an output socket (4) protrudes from one side, in the thickness direction of the printed circuit board (1), of the casing (2). The casing (2) has a bulge part (21) which protruded to an opposite side to the protruding side of the output socket (5) and to which the input socket (3) is fixed.

Abstract: Provided is a printed circuit board (1) on which the power supply circuit is mounted and a casing (2) which is shaped like a flat as a whole and in which the printed circuit board (1) is housed. An input terminal (11) of the power supply circuit is connected to an input socket (3) fixed to one end part, in a direction perpendicular to a thickness direction of the printed circuit board (1), of the casing. An output terminal (12) of the power supply circuit is connected to an output socket (4) protrudes from one side, in the thickness direction of the printed circuit board (1), of the casing (2). The casing (2) has a bulge part (21) which protruded to an opposite side to the protruding side of the output socket (5) and to which the input socket (3) is fixed.

Abstract: A light-emitting-diode-driving device includes a control circuit that is configured to perform constant current control with a DC-DC converter so that a value of a current detected by a current detection unit agrees with a prescribed reference current value to be supplied to a light source. The control circuit includes a reference-current-instruction unit, a threshold-voltage-setting unit, and a comparator circuit. The reference-current-instruction unit is configured to set the prescribed reference current value. The threshold-voltage-setting unit is configured to set a threshold voltage for determining a short circuit failure in the light source. The comparator circuit is configured to compare, with the threshold voltage, a value of a voltage that is detected by a voltage detection unit. The control circuit is configured to make the threshold-voltage-setting unit reduce the threshold voltage, when the reference-current-instruction unit reduces the prescribed reference current value.

Abstract: The present invention provides a prophylactic and/or therapeutic agent for pulmonary hypertension, comprising an antagonistic mutein of MCP-1 or a salt thereof, a DNA molecule comprising a nucleotide sequence encoding the antagonistic mutein of MCP-1, or a neutralizing antibody against MCP-1. The antagonistic mutein of MCP-1 or a salt thereof, the DNA molecule having a nucleotide sequence encoding the antagonistic mutein of MCP-1, or the neutralizing antibody against MCP-1 has hypotensive activity, and thus is useful as a pharmaceutical agent for preventing and/or treating pulmonary hypertension (primary pulmonary hypertension, in particular).

Abstract: The present invention is to provide a sustained-release preparation which comprises a compound having angiotensin II antagonistic activity, its pro-drug or their salt, and a biodegradable polymer, and if necessary, a polyvalent metal, and which is highly stable and active and shows angiotensin II antagonistic activity while maintaining circadian rhythm of blood pressure for a long time.

Abstract: The present invention is to provide a sustained-release preparation which comprises a compound having angiotensin II antagonistic activity, its pro-drug or their salt, and a biodegradable polymer, and if necessary, a polyvalent metal, and which is highly stable and active and shows angiotensin II antagonistic activity with maintaining circadian rhythm of blood pressure for a long time.

Abstract: The present invention provides a prophylactic and/or therapeutic agent for pulmonary hypertension, comprising an antagonistic mutein of MCP-1 or a salt thereof, a DNA molecule comprising a nucleotide sequence encoding the antagonistic mutein of MCP-1, or a neutralizing antibody against MCP-1.

Abstract: The present invention is to provide a sustained-release preparation which comprises a compound having angiotensin II antagonistic activity, its pro-drug or their salt, and a biodegradable polymer, and if necessary, a polyvalent metal, and which is highly stable and active and shows angiotensin II antagonistic activity while maintaining circadian rhythm of blood pressure for a long time.

Abstract: This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula wherein R1 is H or an optionally substituted hydrocarbon residue; R2 is an optionally esterified carboxyl group; R3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R2; and Y is a bond, —O—, —S(O)m- (wherein m is 0, 1 or 2) or —N(R4)— (wherein R4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.

Abstract: This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula wherein R1 is H or an optionally substituted hydrocarbon residue; R2 is an optionally esterified carboxyl group; R3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R2; and Y is a bond, —O—, —S(O)m— (wherein m is 0, 1 or 2) or —N(R4)— (wherein R4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.

Abstract: This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula 1

Abstract: This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula 1

Abstract: This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula wherein R1 is H or an optionally substituted hydrocarbon residue; R2 is an optionally esterified carboxyl group; R3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R2; and Y is a bond, —O—, —S(O)m— (wherein m is 0, 1 or 2) or —N(R4)— (wherein R4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.

Abstract: This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula ##STR1## wherein R.sup.1 is H or an optionally substituted hydrocarbon residue; R.sup.2 is an optionally esterified carboxyl group; R.sup.3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R.sup.2 ; and Y is a bond, --O--, --S(O)m- (wherein m is 0, 1 or 2) or --N(R.sup.4)-- (wherein R.sup.4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.

Abstract: This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula ##STR1## wherein R.sup.1 is H or an optionally substituted hydrocarbon residue; R.sup.2 is an optionally esterified carboxyl group; R.sup.3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R.sup.2 ; and Y is a bond, --O--, --S(O)m-- (wherein m is 0, 1 or 2) or --N(R.sup.4)-- (wherein R.sup.4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.